methyl 2-(1-ethylpropylamino)acetate | 1019627-75-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl 2-(1-ethylpropylamino)acetate
• 英文别名: Methyl [(1-ethylpropyl)amino]acetate；methyl 2-(pentan-3-ylamino)acetate
• CAS: 1019627-75-8
• 化学式: C₈H₁₇NO₂
• mdl: MFCD11099639
• 分子量: 159.228
• InChiKey: IYFIBYCDLACHMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2-(1-ethylpropylamino)acetate 、 2-[(tert-butoxycarbonyl)(1-ethylpropyl)amino]acetic acid 在 4-二甲氨基吡啶 、 N,N'-二异丙基碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 Methyl 2-[[2-[(2-methylpropan-2-yl)oxycarbonyl-pentan-3-ylamino]acetyl]-pentan-3-ylamino]acetate
  参考文献：
  名称：

  UCHP Method for Oligosaccharide Combinatorial Library Synthesis

  摘要：

  A new methodology for oligosaccharide combinatorial library synthesis using a special hydroxy protecting group, the uni-chemo hydroxy protection (UCHP) group, was developed. The UCHP group was composed of oligomeric amino acid derivatives. The amino terminals of UCHP groups were protected by either Boc or Fmoc groups. By using these two types of UCHP, five kinds of trigalactoses [Gal beta 1-3Gal beta 1-3Gal, Gal beta 1-3(Gal beta 1-4) Gal, Gal beta 1-4Gal beta 1-3Gal, Gal beta 1-3Gal beta 1-4Gal, and Gal beta 1-4Gal beta 1-4Gal] were successfully synthesized on a solid support as a model of oligosaccharide combinatorial library. Each step of all reactions was also successfully monitored using a combination of two colorimetric tests, chloranil and methyl red-DIC.

  DOI：

  10.1080/07328300903100661
• 作为产物：
  描述：

  溴乙酸甲酯 、 3-氨基戊烷 以 四氢呋喃 为溶剂， 反应 2.08h， 以92%的产率得到methyl 2-(1-ethylpropylamino)acetate
  参考文献：
  名称：

  UCHP Method for Oligosaccharide Combinatorial Library Synthesis

  摘要：

  A new methodology for oligosaccharide combinatorial library synthesis using a special hydroxy protecting group, the uni-chemo hydroxy protection (UCHP) group, was developed. The UCHP group was composed of oligomeric amino acid derivatives. The amino terminals of UCHP groups were protected by either Boc or Fmoc groups. By using these two types of UCHP, five kinds of trigalactoses [Gal beta 1-3Gal beta 1-3Gal, Gal beta 1-3(Gal beta 1-4) Gal, Gal beta 1-4Gal beta 1-3Gal, Gal beta 1-3Gal beta 1-4Gal, and Gal beta 1-4Gal beta 1-4Gal] were successfully synthesized on a solid support as a model of oligosaccharide combinatorial library. Each step of all reactions was also successfully monitored using a combination of two colorimetric tests, chloranil and methyl red-DIC.

  DOI：

  10.1080/07328300903100661

文献信息

• 2' FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
  申请人：Gilead Sciences, Inc.

  公开号：US20170226140A1

  公开（公告）日：2017-08-10

  Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein R 2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.

  提供了一种通过给予公式I中的核糖苷、核糖苷磷酸和其前药来治疗Orthomyxoviridae病毒感染的方法：其中R2是卤素。所提供的化合物、组合物和方法特别适用于治疗人类流感病毒感染。
• Hydantoin derivative as metalloprotease inhibitor
  申请人：FUJIREBIO INC.

  公开号：EP0640594A1

  公开（公告）日：1995-03-01

  A hydantoin derivative represented by formula (I): wherein the all symbols are defined in the disclosure. The hydantoin derivative has an inhibitory activity on metalloprotease and hence is useful as analgesic and cardiovascular drug.

  一种以化学式(I)表示的噻唑烷酮衍生物：其中所有符号均在披露中定义。该噻唑烷酮衍生物具有对金属蛋白酶的抑制活性，因此可用作镇痛和心血管药物。
• Phosphonate inhibitors of HCV
  申请人：Boojamra G. Constantine

  公开号：US20080107628A1

  公开（公告）日：2008-05-08

  A compound of Formula I, Formula II, Formula III, or Formula IV: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, therapeutic compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

  一种具有I式、II式、III式或IV式的化合物，或其药学上可接受的盐、溶剂和/或酯，包含这种化合物的治疗组合物，以及包括给予这种化合物的治疗方法。
• Aminoalkyl-substituted N-thienylbenzamide derivative
  申请人：ASTELLAS PHARMA INC.

  公开号：US09062032B2

  公开（公告）日：2015-06-23

  [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

  [问题] 提供一种具有肠道磷酸转运体（NPT-IIb）抑制作用并可用作治疗和/或预防高磷血症药物的有效成分的化合物。 [解决方法] 现有发明人对具有NPT-IIb抑制作用并可用作治疗和/或预防高磷血症药物的有效成分的化合物进行了研究。结果，他们创造了一种具有NPT-IIb抑制作用的氨基烷基取代N-噻吩基苯甲酰胺衍生物，从而完成了本发明。本发明的氨基烷基取代N-噻吩基苯甲酰胺衍生物具有NPT-IIb抑制作用，并可用作预防和/或治疗高磷血症的药物。
• AMINOALKYL-SUBSTITUTED N-THIENYLBENZAMIDE DERIVATIVE
  申请人：ASTELLAS PHARMA INC.

  公开号：US20150031727A1

  公开（公告）日：2015-01-29

  [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

  【问题】提供一种具有肠道磷酸转运体（NPT-IIb）抑制作用并且可用作治疗和/或预防高磷血症药物的活性成分的化合物。【解决方案】本发明人对一种具有NPT-IIb抑制作用并且可用作治疗和/或预防高磷血症药物的活性成分的化合物进行了研究。结果，他们创造了一种具有NPT-IIb抑制作用的氨基烷基取代的N-噻吩基苯酰胺衍生物，从而完成了本发明。本发明的氨基烷基取代的N-噻吩基苯酰胺衍生物具有NPT-IIb抑制作用，并可用作预防和/或治疗高磷血症的药物。